Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.
Marthe M de JongeAurélie AugusteLise M van WijkPhilip C SchoutenMatty MeijersNatalja T Ter HaarVincent T H B M SmitRemi A NoutMark A GlaireDavid N ChurchHarry VrielingBastien JobYannick BoursinCor D de KroonEtienne RouleauAlexandra LearyMaaike P G VreeswijkTjalling BossePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
HRD occurs in endometrial cancers and is largely restricted to non-endometrioid, TP53-mutant endometrial cancers. Evaluation of HRD may help select patients that could benefit from treatments targeting this defect, including platinum compounds and PARP inhibitors.